复发性复发性多发性硬化症患者的功能和认知障碍:认知测试和血神经纤维光链水平
Elina Polunosika1,2, Joel Simren3,4, Arta Akmene1
1Department of Neurology and Neurosurgery, Riga East University Hospital, LV-1038 Riga, Latvia.
Medicina (Kaunas, Lithuania)
|January 25, 2025
概括
与对照组相比,多发性硬化症 (MS) 患者表现出认知处理速度和精细运动技能受损. 这些缺陷与神经障碍和MS中血神经丝光链 (pNfL) 水平升高相关.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 多发性硬化症 (MS) 是一种慢性,炎症性,自身免疫性和神经退行性中枢神经系统疾病.
- 多发性硬化呈现出影响日常生活的身体和认知症状.
- 了解功能状态,认知和生物标志物之间的关系对于MS管理至关重要.
研究的目的:
- 研究MS患者的功能状态,认知功能和血神经丝光链 (pNfL) 水平之间的相关性.
- 为了比较多发性硬化患者和健康对照组之间的认知和运动性能.
- 探索教育水平对MS认知表现的影响.
主要方法:
- 横截面研究包括42名复发性复发性MS患者和42名对照人群.
- 使用扩展残疾状态量表 (EDSS) 评估的功能状态.
- 使用符号数字模式测试 (SDMT) 和简要视觉空间记忆测试修订 (BVMT-R) 评估认知功能.
- 用九孔测试 (9-HPT) 评估精细运动技能.
- 使用Simoa技术测量的等离子神经纤维光链 (pNfL) 水平.
主要成果:
- 与对照组相比,MS患者在SDMT上的表现较慢 (中位数为81.3比94.0).
- 在MS患者中,较慢的SDMT性能与较高的EDSS得分相关.
- 多发性硬化患者在使用主导手的9-HPT上表现出较慢的执行反应速度 (24.1s vs 19.4s).
- 一个趋势表明,MS患者的SDMT表现较慢,与较高的PNfL水平相关.
- 在两组中,更高的教育水平与更好的认知处理速度和记忆有关.
结论:
- 在MS患者中存在认知和精细运动功能障碍.
- 这些神经障碍与血神经丝光链 (pNfL) 水平相关.
- pNfL可能作为神经损伤和MS功能衰退的生物标志物.
相关概念视频
Negative and Cognitive Symptoms of Schizophrenia
40
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
40
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95


